Tag

Sanofi

All articles tagged with #sanofi

business1 month ago•3 min saved

Sanofi shelves mRNA seasonal flu effort, pivots to proven vaccines

Sanofi has deprioritized its phase 1 mRNA seasonal flu program, scrapping the effort as part of a broader strategic shift, while continuing to pursue an mRNA vaccine for an H5 pandemic and focusing on established influenza vaccines (Fluzone High-Dose, Flublok). The influenza/COVID vaccine franchise generated €2.3 billion last year, a 6% decline from 2024 amid lower US immunization rates, and the company underscored a multi‑platform vaccine strategy, including the Dynavax acquisition, as its growth path.

via Fierce Biotech|

#business #influenza-vaccines #mrna-vaccines

health1 month ago•39 min saved

FDA slows two fast-track drug reviews amid safety flags in voucher plan

Reuters reports the U.S. FDA has delayed reviews of two drugs selected for the National Priority Voucher fast-track program after agency scientists flagged safety and efficacy concerns, including a treatment-related death linked to one drug. Disc Medicine's experimental therapy for a rare blood disorder was pushed back due to questions about trial data and abuse risk, while Sanofi's Tzield for late-stage type 1 diabetes was delayed over adverse events, including seizures and a death. Two other program drugs—Boehringer Ingelheim's zongertinib and Lilly's weight-loss pill—were also delayed by weeks. The delays underscore the program’s aim to accelerate reviews only when warranted by robust safety/efficacy data, amid ongoing scrutiny of how political factors may influence drug decisions.

via Yahoo|

#disc-medicine #fda #health

business2 months ago•3 min saved

Sanofi's $2.2 Billion Acquisition of Dynavax Boosts Vaccine Portfolio

Sanofi is acquiring U.S. biotech Dynavax for $2.2 billion to expand its adult vaccine portfolio, including hepatitis B and shingles vaccines, aiming to diversify and boost revenue growth amid regulatory and market pressures. The deal, expected to close in early 2026, also includes an experimental shingles vaccine with potential long-term sales, while Sanofi faces setbacks with an FDA rejection of its multiple sclerosis drug.

via CNBC|

#acquisition #biotech #business

business2 months ago•1 min saved

European Markets Reach New Highs Amid Pharma Gains and Economic Growth

European markets closed mixed with Novo Nordisk shares jumping 9.2% after FDA approval for a GLP-1 pill, while Sanofi announced a $2.2 billion acquisition. Gold and silver futures hit new highs, and U.S. visa bans were imposed on EU officials involved in social media censorship. Asia-Pacific markets traded mostly higher, and U.S. futures remained flat despite record closes for the S&P 500.

via CNBC|

#business #european-markets #glp-1-pill

healthcare7 months ago•2 min saved

Apogee's Eczema Drug Shows Promising Results, Challenging Industry Leaders

Apogee Therapeutics' promising eczema drug showed strong efficacy in Phase 2 trials, outperforming rivals like Sanofi's Dupixent, but its shares fell sharply after the announcement. The drug could potentially rival Sanofi's top revenue-generating treatments if further trials succeed, with plans for Phase 3 testing in 2026.

via Investor's Business Daily|

#apogee-therapeutics #clinical-trial #drug-development

business9 months ago•0 min saved

Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal

Sanofi is acquiring Blueprint Medicines for $9.1 billion to strengthen its rare immunology portfolio, marking the largest biopharma deal since January.

via Endpoints News|

#acquisition #ayvakit #biopharma

health9 months ago•1 min saved

Regeneron and Sanofi's COPD Drug Shows Mixed Results in Phase 3 Trials

A key Phase 3 trial of Regeneron and Sanofi's COPD drug, itepekimab, failed to meet its primary endpoint, causing a significant drop in their stock prices, although one of the two trials showed a meaningful benefit. The companies are reviewing the data and consulting with regulators to determine next steps.

via Investopedia|

#clinical-trial #copd #health

business9 months ago•1 min saved

Regeneron and Sanofi's Respiratory Drugs Show Mixed Results in Recent Trials

Regeneron Pharmaceuticals' stock dropped 12% after its COPD drug, developed with Sanofi, failed in a Phase 3 trial, with mixed results across two studies, potentially hindering approval efforts.

via Investor's Business Daily|

#business #copd #drug-failure

health1 year ago•6 min saved

Sanofi's Rilzabrutinib Shows Promise in Treating Rare Platelet Disorder

Sanofi's rilzabrutinib, an oral treatment for immune thrombocytopenia (ITP), showed promising results in a Phase 3 trial, improving platelet response and reducing bleeding episodes. The drug, a bruton's kinase inhibitor, is safer and better tolerated than existing treatments, potentially setting a new standard for ITP therapy. Meanwhile, Novo Nordisk's etavopivat reduced severe pain crises in sickle cell disease patients in a Phase 2 study, though results were not statistically significant. Beam Therapeutics' CRISPR-based therapy for sickle cell disease also showed consistent positive results, with no severe pain crises reported among treated patients.

via STAT|

#health #immune-thrombocytopenia #novo-nordisk

health-medical-research1 year ago•2 min saved

"GLP-1 Diabetes Drug Slows Parkinson's Progression in Small Trial"

A small mid-stage trial has shown that the diabetes drug lixisenatide, similar to Ozempic, helped slow the progression of motor disability in patients with early-stage Parkinson's disease. The drug, made by Sanofi, demonstrated potential in mitigating symptoms such as tremors and stiffness, but was also associated with an increased risk of gastrointestinal side effects. Larger and longer studies are needed to fully determine the efficacy and safety of this treatment for Parkinson's disease.

via CNBC|

#diabetes-drug #health-medical-research #lixisenatide

legalpharmaceuticals1 year ago•2 min saved

Sanofi Settles Thousands of Zantac Cancer Lawsuits in US

Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, without disclosing the financial terms. The settlement, which still needs to be finalized, will resolve most of the lawsuits against the French pharmaceutical company in U.S. state courts, except for Delaware. Sanofi did not admit any liability in the settlement and stated that it is settling to avoid the expense and ongoing distraction of the litigation. The company still faces about 20,000 lawsuits over Zantac in Delaware state court, and a judge is considering the fate of approximately 70,000 cases filed against Sanofi and other defendants.

via Reuters|

#cancer-lawsuits #legalpharmaceuticals #pharmaceutical-industry

healthcare2 years ago•0 min saved

Sanofi and AstraZeneca's RSV Antibody Faces Limited Supply Amid High Demand

Sanofi anticipates limited supply of its infant RSV antibody Beyfortus, co-developed with AstraZeneca, in the first quarter of this year due to overwhelming demand, with plans to boost production but uncertainty about the extent of progress that can be made in 2024. CEO Paul Hudson highlighted efforts to address manufacturing bottlenecks and increase capacity to tackle supply constraints.

via Endpoints News|

#astrazeneca #beyfortus #healthcare

business2 years ago•1 min saved

Sanofi's $2.2 Billion Acquisition of Inhibrx for Rare-Disease Drug

French healthcare company Sanofi has agreed to acquire U.S. biotech firm Inhibrx for up to $2.2 billion, gaining access to the experimental drug INBRX-101 designed to treat Alpha-1 Antitrypsin Deficiency. The deal includes spinning off Inhibrx's other experimental drugs into a separate company, with Sanofi retaining an 8% stake, and Inhibrx shareholders receiving $30 per share in cash plus shares in the spun-off company. This acquisition aligns with Sanofi's strategy to focus on differentiated and potential best-in-class products, reinforcing its rare disease portfolio.

via Reuters.com|

#acquisition #business #inhibrx

business-healthcare2 years ago•0 min saved

Sanofi's $2.2B Acquisition of Inhibrx Strengthens Drug Pipeline

Sanofi is acquiring California-based biotech company Inhibrx for up to $2.2 billion to bolster its pipeline of inflammation-targeting drugs, with a focus on Inhibrx’s experimental therapy for AATD, a disease affecting the lungs and liver. Inhibrx's other drug candidates, including cancer-targeting immunotherapies, will be part of a new company led by Inhibrx's founder and CEO.

via STAT|

#acquisition #biotech #business-healthcare

business-healthcare2 years ago•0 min saved

Sanofi's $2.2B Acquisition of Inhibrx for Rare Disease Drug

Sanofi is acquiring Inhibrx for $1.7 billion, primarily for its lead drug designed to treat alpha-1 antitrypsin deficiency (AATD) and plans to retain an 8% equity stake in the spun-out company New Inhibrx, while the other programs will be separated into this new entity.

via Endpoints News|

#acquisition #biopharmaceutical #business-healthcare